This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Abbott Laboratories stock in Canada | $109.48

Own Abbott Laboratories shares in just a few minutes.

Posted

Fact checked

Abbott Laboratories is a medical devices business based in the US. Abbott Laboratories shares (ABT.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $109.48 – a decrease of 0.17% over the previous week. Abbott Laboratories employs 107,000 staff and has a trailing 12-month revenue of around $32.2 billion.

How to buy shares in Abbott Laboratories

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: ABT in this case.
  5. Research Abbott Laboratories shares. The platform should provide the latest information available.
  6. Buy your Abbott Laboratories shares. It's that simple.

How has Coronavirus impacted Abbott Laboratories's share price?

Since the stock market crash in March caused by coronavirus, Abbott Laboratories's share price has had significant positive movement.

Its last market close was $109.48, which is 20.12% up on its pre-crash value of $87.45 and 77.70% up on the lowest point reached during the March crash when the shares fell as low as $61.61.

If you had bought $1,000 worth of Abbott Laboratories shares at the start of February 2020, those shares would have been worth $721.80 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,257.93.

Abbott Laboratories share price

Use our graph to track the performance of ABT stocks over time.

Abbott Laboratories shares at a glance

Information last updated 2020-12-02.
Latest market close $109.48
52-week range $60.9114 - $115.14
50-day moving average $109.3357
200-day moving average $101.3768
Wall St. target price $119.94
PE ratio 57.1391
Dividend yield $1.44 (1.33%)
Earnings per share (TTM) $1.891

Compare online trading platforms

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Buy and sell thousands of US and Canadian stocks and ETFs commission-free with Wealthsimple Trade.
Interactive Brokers
Stocks, Bonds, Options, Mutual Funds, ETFs, Currencies, Futures, Precious Metals
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are equal to or greater than US$10.00)
Min. $1.00, Max. 0.5% of trade value
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, IPOs, Precious Metals
$4.95 - $9.95
$9.95 + $1 per contract
$0
Free
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
loading

Compare up to 4 providers

Name Product Minimum deposit to invest Funding methods Management fee Available asset types
CI Direct Investing (formerly WealthBar)
$1,000
Direct deposit, Bank transfer
0.35% - 0.60%
Mutual Funds, ETFs
CI Direct Investing offers access to an exclusive and personalized investment portfolio. Get up to $10,000 managed free for a year when you sign up for your first CI Direct Investing account and fund your account.
Moka
$0
Automatic bank withdrawals
$3/month
ETFs
The Moka app rounds up every purchase you make to the nearest dollar and invests the spare change into low-cost exchange-traded funds (ETFs).
Justwealth
$5,000
Direct deposit, Bank transfer, Automatic bank withdrawals
0.50%
ETFs
Receive a cash bonus of $50.00-$225.00 when you open a new Justwealth account. RESP accounts require no minimum deposit to begin investing.
Wealthsimple Invest
$1
Direct deposit, Bank transfer
0.40% - 0.50%
Stocks, Bonds, ETFs, Commodities
Get a $50 bonus when you open and fund your first Wealthsimple Invest account with a minimum initial deposit of at least $500. Trade and Cash accounts are not eligible.
loading

Compare up to 4 providers

Name Product Minimum Opening Deposit Commission Available Markets Platforms
Forex.com
US$100
Minimum US$25
Forex
Metals
Commodities
Indices
Shares
Forex.com Desktop, Forex.com Web Trading, Forex.com Mobile Trading, MetaTrader 4
CFDs are leveraged products which involves greater risk than using cash resources only. You could lose all or more of your initial investment. Trade 80+ currency pairs and 220+ CFDs in equities, commodities and indices on Forex.com.
loading

Compare up to 4 providers

Is it a good time to buy Abbott Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Abbott Laboratories price performance over time

Historical closes compared with the last close of $109.48

1 week (2020-11-27) 1.73%
1 month (2020-11-05) -3.57%
3 months (2020-09-04) 5.11%
6 months (2020-06-05) 21.83%
1 year (2019-12-05) 28.44%
2 years (2018-12-04) 53.12%
3 years (2017-12-05) 99.82%
5 years (2015-12-04) 141.68%

Is Abbott Laboratories under- or over-valued?

Valuing Abbott Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abbott Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Abbott Laboratories's P/E ratio

Abbott Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 57x. In other words, Abbott Laboratories shares trade at around 57x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Abbott Laboratories's PEG ratio

Abbott Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.4135. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abbott Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Abbott Laboratories's EBITDA

Abbott Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$7.8 billion.

The EBITDA is a measure of a Abbott Laboratories's overall financial performance and is widely used to measure a its profitability.

Abbott Laboratories financials

Revenue TTM USD$32.2 billion
Operating margin TTM 14.3%
Gross profit TTM USD$18.7 billion
Return on assets TTM 4.19%
Return on equity TTM 10.57%
Profit margin 10.5%
Book value $17.709
Market capitalisation USD$191.5 billion

TTM: trailing 12 months

How to short and sell Abbott Laboratories shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "ABT.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 11.8 million Abbott Laboratories shares held short by investors – that's known as Abbott Laboratories's "short interest". This figure is 26.2% up from 9.4 million last month.

There are a few different ways that this level of interest in shorting Abbott Laboratories shares can be evaluated.

Abbott Laboratories's "short interest ratio" (SIR)

Abbott Laboratories's "short interest ratio" (SIR) is the quantity of Abbott Laboratories shares currently shorted divided by the average quantity of Abbott Laboratories shares traded daily (recently around 5.2 million). Abbott Laboratories's SIR currently stands at 2.28. In other words for every 100,000 Abbott Laboratories shares traded daily on the market, roughly 2280 shares are currently held short.

However Abbott Laboratories's short interest can also be evaluated against the total number of Abbott Laboratories shares, or, against the total number of tradable Abbott Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abbott Laboratories's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Abbott Laboratories shares in existence, roughly 10 shares are currently held short) or 0.0069% of the tradable shares (for every 100,000 tradable Abbott Laboratories shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Abbott Laboratories.

Find out more about how you can short Abbott Laboratories stock.

Abbott Laboratories's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Abbott Laboratories.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Abbott Laboratories's total ESG risk score

Total ESG risk: 32.35

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Abbott Laboratories's overall score of 32.35 (as at 01/01/2019) is pretty weak – landing it in it in the 61st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Abbott Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Abbott Laboratories's environmental score

Environmental score: 3.98/100

Abbott Laboratories's environmental score of 3.98 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Abbott Laboratories's social score

Social score: 20.71/100

Abbott Laboratories's social score of 20.71 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Abbott Laboratories's governance score

Governance score: 13.15/100

Abbott Laboratories's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Abbott Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Abbott Laboratories's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Abbott Laboratories scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Abbott Laboratories hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Abbott Laboratories was last rated for ESG on: 2019-01-01.

Total ESG score 32.35
Total ESG percentile 60.66
Environmental score 3.98
Environmental score percentile 5
Social score 20.71
Social score percentile 5
Governance score 13.15
Governance score percentile 5
Level of controversy 3

Abbott Laboratories share dividends

46%

Dividend payout ratio: 45.71% of net profits

Recently Abbott Laboratories has paid out, on average, around 45.71% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.33% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Abbott Laboratories shareholders could enjoy a 1.33% return on their shares, in the form of dividend payments. In Abbott Laboratories's case, that would currently equate to about $1.44 per share.

While Abbott Laboratories's payout ratio might seem fairly standard, it's worth remembering that Abbott Laboratories may be investing much of the rest of its net profits in future growth.

Abbott Laboratories's most recent dividend payout was on 16 November 2020. The latest dividend was paid out to all shareholders who bought their shares by 14 October 2020 (the "ex-dividend date").

Have Abbott Laboratories's shares ever split?

Abbott Laboratories's shares were split on a 10000:4798 basis on 2 January 2013. So if you had owned 4798 shares the day before before the split, the next day you'd have owned 10000 shares. This wouldn't directly have changed the overall worth of your Abbott Laboratories shares – just the quantity. However, indirectly, the new 52% lower share price could have impacted the market appetite for Abbott Laboratories shares which in turn could have impacted Abbott Laboratories's share price.

Abbott Laboratories share price volatility

Over the last 12 months, Abbott Laboratories's shares have ranged in value from as little as $60.9114 up to $115.14. A popular way to gauge a stock's volatility is its "beta".

ABT.US volatility(beta: 0.89)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Abbott Laboratories's is 0.8935. This would suggest that Abbott Laboratories's shares are less volatile than average (for this exchange).

Abbott Laboratories overview

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Go to site